UNSPSC 51362601: Gabapentin

This classification denotes a sedative and hypnotic with the molecular formula C9H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6CW7F3G59X, chemically known as cyclohexaneacetic acid, 1-(aminomethyl)- but generally known as gabapentin, which bears US NIH Compound Identifier 3446. European Medicines Agency schedules Gabapentin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07857MIG. The term GABAPENTIN is an International Non-Proprietary Name.

UNSPSC 51362601 Gabapentin is a Commodity code that nominally identifies a specific pharmaceutical product, yet the recent state and local opportunities posted under this code show significant scope drift — solicitations are tagged to gabapentin but actually procure naloxone, drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products. State and local procurement offices are using this code to buy pharmaceutical sourcing and distribution services, pharmacy benefit management capabilities, and pharmaceutical supply chain access rather than gabapentin itself. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple jurisdictions including Oregon). The scope reflects broader pharmaceutical procurement and supply chain modernization activity rather than purchase of a single drug product.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County released an IFB on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, including all shipping and delivery costs in vendor proposals. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct state relationships with pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awarded vendors effective July 1, 2026 and contract term through June 30, 2028. The mismatch between code name and solicitation scope signals that this Commodity code may be misapplied to pharmaceutical procurement more broadly rather than tracking gabapentin-specific purchases.